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Abstract
Background. Adolescent development of the prefrontal cortex (PFC) 
is accompanied by important changes in glutamatergic, GABAergic 
and dopaminergic circuitries, susceptible to modulation by 
N-methyl-D-aspartate receptors (NMDAR) antagonists. Repeated 
ketamine was associated with social and memory deficits, but other 
relevant factors, such as anxiety, were not sufficiently addressed. 
The present study aimed to examine the behavioral and molecular 
consequences of repeated exposure to ketamine with a particular 
focus in anxiety. Methods. We treated male adolescent Wistar rats, 
starting postnatal day (PND) 35, with ketamine (30 mg/kg, i.p, 7 
days). Behavioral evaluation was conducted in the adulthood (PND 
60). The elevated plus maze (EPM) and open field tests were used 
to evaluate anxiety and locomotion, while sociability and novelty 
recognition were assessed through the novel object recognition 
(NOR) and the sociability and social novelty tests. At the end of 
the behavioral evaluation, brains were dissected and the prefrontal 
cortex used for biochemical evaluation. Results. Analysis of the 
elevated plus maze (EPM) data revealed a ketamine-induced 
anxiety-like profile, corroborated by the open field data. Ketamine-
treated rats also failed to increase contact time with a conspecific 
in the social affiliation test and with an unknown rat in the novelty 
preference test. At the molecular level, frontal expression levels 
of tyrosine hydroxylase were found decreased. Conclusion. 
Altogether, these results show that repeated ketamine-exposure in 
the adolescent may result in long-term anxiety.
Keywords ketamine; NMDAR; adolescent; anxiety; schizophrenia; 
prefrontal cortex
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1. Introduction 
Non-competitive N-methyl-D-aspartate receptor 
(NMDAR) antagonists, such as phencyclidine (PCP), 
dizocilpine (MK-801) and ketamine are known to 
modulate the prefrontal function and hence often used 
in rat and mouse models to mimic schizophrenia-like 
symptoms [1]. Initial evidence for these models comes 
from the recreational use of PCP that leads to delusion, 
hallucination and other psychotic behaviour in healthy 
subjects [2]. Importantly, different administration 
schedules were seen to result in substantially diverse 
outcomes as reviewed by Jones et al. [3] Typically, 
poor social interaction [4], anhedonia [5], and deficits in 
learning, memory or attention [3] were reported in NMDA 
antagonist models. These changes were associated with 
frontal dopaminergic hypofunction [6], abnormal cortical 
levels of glutamate [7] and decreased parvalbumin in 
the prefrontal cortex (PFC) and hippocampus [5,8]. 
Monoaminergic receptors were also affected in several 
brain regions [9,10]. Preclinical studies also report 
that sub-anesthetic doses of ketamine in adult rats may 
result in other schizophrenia-associated features such as 
nitrergic and GABAergic alterations in the hippocampus 
[11]; long-term increase of type-2 dopamine receptor 
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(DR2) binding in the hippocampus; decreased glutamate 
receptor binding in the PFC [12]; increased cortical levels 
of glutamate [13]; and a steady decline of both gamma 
and theta hippocampal oscillations correlated to reduced 
parvalbumin interneurons [14]. 
Because the use of NMDAR antagonists and 
other psychoactive substances [15,16] in adolescence 
is frequently associated with the development of 
schizophrenic-like symptoms and psychosis, addressing 
exposure to ketamine during this developmental 
period could have increased etiological relevance [17]. 
Importantly, anxiety and poor sociability are often present 
at the onset of drug use/abuse, and may precede the 
arrival of psychotic surges [18,19]. In previous studies, 
chronic ketamine in adolescent rats resulted in impaired 
social behavior and memory deficits after 7 days of 25 
mg/kg [20], while other authors reported memory deficits 
after 7 days of 80 mg/kg of ketamine, but not after 30 
mg/kg [21]. In a different study adolescent rats exposed 
to ketamine (30 mg/kg, 5 days) displayed impaired 
pre-pulse inhibition and compromised memory [22]. 
However, chronic ketamine (20 mg/kg, twice a day) in 
the adolescent rat was also reported to endure resilience 
and presumed useful as an antidepressant [23]. Of note, 
repeated administration of 10 mg/kg dose was recently 
shown to elicit condition place preference in male rats 
[24]. In previous studies, behavioral evaluation was 
usually focused on domains related to attention, working 
memory, problem solving and social deficits [17], while 
anxiety-like symptoms were mostly neglected [3].
Here, aiming to better understand the effect of repeated 
ketamine in adolescent rats in anxiety and sociability, 
we exposed male adolescent Wistar rats to daily doses 
of 30 mg/kg of ketamine for 7 days. Evaluations were 
conducted at the onset of adulthood.
2. Methods
2.1 Animals 
A total of 10 males born from primiparous three-
month old SPF Wistar females were used in this study 
(acquired from Charles River Laboratories, Barcelona, 
Spain). Adolescent females were excluded because the 
estrous cycle was recently demonstrated to interfere with 
anxiety levels in Wistar rats [25]. Animals were kept 
under stable conditions (20-22°C, 60% humidity) in an 
inverted 12-hour light/dark cycle, with water and food 
supplied ad libitum. Cylindrical card tubes and soft paper 
were made available. All procedures used were approved 
by local ethical committee and by the Portuguese 
Agency for Animal Welfare, general board of Veterinary 
Medicine (ref. 0421/000/000/2013), in compliance 
with the 2010 European Community Council Directive 
(2010/63/UE) and the ARRIVE guidelines. Procedures 
involving animals were conducted by FELASA C graded 
researchers and all efforts were made to minimize stress 
and discomfort.
At postnatal (PND) 30, adolescent male rats 
from different litters were randomly assigned to an 
experimental group and housed in pairs. From PND35, 
one rat per cage received a daily intraperitoneal 
administration of 30 mg of ketamine/kg of body weight, 
in a volume of 1 mL/kg, while the other rat received 
isovolumetric saline (NaCl 0.9% w/v). Doses were 
administered one hour before the end of the dark period 
for seven consecutive days following previously reported 
schedules [11,12]. Ketamine (Imalgene1000®, 100 mg/
ml, racemic formulation) was obtained from Merial 
Portuguesa (Rio de Mouro, Portugal). Weight gain was 
controlled during the administration period. Behavioral 
assessment started at PND60, a time-point that matches 
the beginning of adulthood [26]. Rats were killed after 
the last behavioral evaluation by decapitation and brains 
were collected, dissected on ice and kept at -80°C until 
processed.
2.2 Behavioral testing
Behavioral testing were performed in the adulthood 
(PND60). All tests were conducted in the dark phase of 
the light cycle, in a room adjacent to the maintenance 
area. All apparatus were thoroughly cleaned with neutral 
soap after each session. All evaluations were conducted 
in a blind manner.
2.3 Elevated plus-maze (EPM)
Rats were allowed to explore the maze individually 
for 5 minutes. Evaluated parameters: i) number of 
entries and time spent in open or closed arms and central 
platform; ii) self-grooming; iii) exploratory behavior; 
and iv) head dipping (HD) (head and shoulders over the 
edge of the maze) [27]. HD was considered protected 
(PHD) if the posterior paws were in the closed arms or 
central area, and unprotected if all paws were on open 
arms. Distal HD (DHD) took place on the distal one-third 
of the open arm. Video data were analyzed using the 
Observer 5 software (Noldus Information Technology, 
Wageningen, The Netherlands).
2.4 Open field
Each rat was placed in the center of an arena and 
allowed to move freely for 10 m. The distance travelled, 
peripheral activity or thigmotatic behavior (locomotion 
along the walls) and center activity (locomotion in the 
central area) were automatically obtained through video 
tracking (Smart Video Tracking Software v 2.5, Panlab).
2.5 Novel object recognition (NOR)
The NOR test was performed as previously described 
[28]. During the habituation phase rats explored the 
apparatus for 10 min. The acquisition/sample phase 
started a day after by placing each rat in the apparatus 
with two identical objects (familiar object) for 10 min 
(Figure 1A, 2A). After 24 hours (inter-trial interval), the 
retention/choice session was performed. In this phase, a 
novel object and a copy of the familiar object were used. 
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Rats were again allowed to explore the objects for 10 
min (Figure 3A). Exploration was defined as follows: rat 
nose touching or directed towards the object at a distance 
shorter than 2 cm [29]. The discrimination index (DI) was 
calculated as the ratio TN/(TN+TF) [TN=time exploring 
the novel (N) object; TF=time exploring the familiar (F) 
object][29].
2.6 Sociability and social novelty
The apparatus contained three-chambers separated by 
clear plexiglas walls with doors. Each tested rat was 
placed in the central chamber and allowed to habituate 
for 5 min. Testing was conducted as previously 
described [30]. During the social affiliation test, each 
rat was allowed to choose between the chamber with an 
unfamiliar rat (restrained in a containment cup, stranger 
I) or an empty cup (Figure 2D). The time spent around 
each cup was registered. For the social preference test, 
an additional rat (stranger II) was placed in the empty 
chamber (within the containment cup, Figure 2F). The 
experimental rat was allowed to explore the apparatus 
and the time spent around each conspecific was registered 
(contact time). Both tests lasted 10 min. Video data 
were analyzed using the Observer 5 software (Noldus 
Information Technology).
2.7 Quantitative real-time polymerase chain reaction 
(qRT-PCR)
Since the prefrontal cortex is a brain region highly 
affected by ketamine [31,32], total RNA was isolated from 
the prefrontal cortex tissue using the iTaqTM Universal 
kit (Invitrogen, Carlsbad, CA, USA). RNA quality was 
confirmed in an agarose gel and RNA concentration 
determined in a NanoDrop™ 1000 (Thermo Fisher 
Scientific, Wilmington, Delaware, USA). Synthesis of 
cDNA was performed using the NZY First-Strand cDNA 
synthesis kit (Invitrogen) and 1 µg of RNA was used. The 
qRT-PCR reactions for the different genes, tyrosine 
hydroxylase (TH) and dopamine receptor 1 (DR1) and 
DR2, were performed on the iQ5 Multicolor Real-time 
PCR Detection System from Bio-Rad Laboratories 
(Hercules, CA, USA), using the iQTM SYBR® 
Green Supermix (Bio-Rad Laboratories, Hercules, 
CA, USA). mRNA quantification was performed 
by comparative threshold cycle quantification 
(ΔCt method) using glyceraldahyde-3-phosphate-
dehydrogenase (GAPDH) as a reference gene. The 
primers used were obtained from Sigma (St. Louis, 
MO): TH sense primer: 5’-GGC TTC TCT GAC CAG 
GTG TAT C-3’; TH antisense primer: 5’-CAA TCT CTT 
CCG CTG TGT ATT CC-3’; D1R sense primer: 5’-ACT 
CTG TCT GTC CTT ATA TCC TCC-3’; D1R antisense 
primer – 5’-GTT GTC ATC CTC GGT GTC C 3´; D2R 
sense primer: 5’-CAA CAA TAC AGA CCA GAA TGC 
GTG-3’; D2R antisense primer 5’-CAG CAG AGT GAC 
GAT GAA GG 3’; GAPDH sense primer: 5’-TTC AAC 
GGC ACA GTC AAG g-3’; GAPDH antisense primer: 
5’-CTC AGC ACC AGC ATC ACC-3’. 
2.8 Western blot
Brain tissue from the prefrontal cortex was also 
homogenized in lysis buffer (50 mM Tris–HCl, 2 mM 
EDTA, 150 mM NaCl, 0.5% NP-40, 1% Triton X-100, 
supplemented with 1:500 Protease Inhibitor Cocktail, 
Sigma, St. Louis, MO, USA) and centrifuged at 16 000 
g for 10 min at 4°C. Total protein concentration was 
estimated in the supernatant by the Bradford method (Bio-
Rad Protein Assay, Munich, Germany). Protein samples 
were resolved by SDS-PAGE on 12% polyacrylamide 
gels or by tricine-SDS-PAGE for parvalbumin, and 
transferred to PVDF membranes by electroblotting. 
Membranes were blocked with BSA 5% and incubated 
with one of the following: Rabbit anti-PSD-95 (Cell 
Signaling Technology, #3450, 1:1000), goat anti-
GAD-67 (Santa Cruz Biotechnology, sc-7512, 1:300), 
mouse anti-NMDAR1 (Millipore, MAB363, 1:500) 
and rabbit anti-parvalbumin (Abcam, ab11427, 0.3 μg/
ml); or blocked with dry milk and incubated with rabbit 
anti-VGLUT (Synaptic Systems, 135 303, 1:5000). A 
mouse anti-GAPDH (Hytest, #5G4, 1:100000) primary 
antibody was used in all membranes for loading control. 
The secondary antibody HRP (horseradish peroxidase)-
conjugated was used for 1 h. Chemiluminescent signal 
detection was achieved using the Immun-Star HRP kit 
(Bio-Rad Laboratories). A GS800 densitometer (Bio-
Rad Laboratories) and quantity one 1-D analysis software 
(v4.6, Bio-Rad) were used for analysis. 
2.8 Statistical analyses
Weight evolution through the experimental period 
was analyzed using two-way ANOVA (Time x 
Treatment) with repeated measures followed by the 
Sidak multiple comparisons test. Unpaired Student´s 
two-tailed t-test was used to compare ketamine treated 
animals with the control group in the EPM, open field 
and NOR tests, and also for molecular data. Two-way 
ANOVA (Treatment x Social/Novelty preference) 
followed by the Sidak multiple comparisons test was 
used to analyze data from social and novelty preference 
tests. Statistical significance was set at P<0.05. Data 
were presented as mean ± SEM. All tests were conducted 
using the GraphPad-Prism software. version 7.00 for 
Mac Os X (GraphPad Software, Inc., San Diego, CA). 
The G*Power 3.1 software [33] was used to ensure that 
the achieved power in each test was above 0.95. Critical 
t-value were also considered.
3. Results
3.1 Ketamine exposure did not affect weight evolution 
Analysis of body weight revealed no differences 
between ketamine-treated rats and control rats for all 
examined time points (Sup. Figure 1, F(7,56)=2.527, 
P=0.1506). Of note, no differences were observed 
between the initial body weight in both groups 
(P(U=11)=0.8175). Of note, no signs of discomfort were 
observed during the entire experimental period. 
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3.2 Ketamine induced anxiety-like behavior 
To assess the effect of ketamine in anxiety, rats 
were tested in the EPM at PND60. Ketamine-treated 
rats showed decreased time spent in the center platform 
(P(t=3.04, dF=8)=0.0161, Figure 1A) and increased time in 
closed arms (P (t=2.436 dF=8)=0.0408, Figure 1A), which 
was concomitant with reduced frequency of entries in 
open arms for the ketamine group (P(t=2.554, dF=8)=0.0340, 
Figure 1B). No differences were observed in total arm 
entries, a measure of global activity (Figure 1C, P(t=1,824 
dF=8)=0.1056). Environment exploratory scanning was 
higher in ketamine-treated rats (Figure 1D, P(t=3.041, 
P(t=3.041, dF=8)=0.0161). The time spent in DHD, a measure 
of exploration, was decreased in ketamine-exposed rats 
(P(U=2.5)=0.0476, Figure 1E). 
The open field test was conducted 2 days after 
the EPM. In this test, the percent of time spent in the 
peripheral area was increased in ketamine-treated rats, 
while the percent of time in the center was decreased 
for the same group (P(t=2.519, dF=8)=0.0359 for both, Figure 
1F). There was no significant difference in the total 
distance traveled by both groups (P=(t=1.092, dF=8)=0.3067, 
Figure1 G). 
3.3 Ketamine decreased the exploration and social 
novelty preference
The NOR was used to evaluate the impact of the 
selected ketamine administration schedule in novelty 
recognition. As plotted in Figure 2B, both groups 
were able to discriminate between the novel and the 
familiar object as traduced by the discrimination index 
(P(t=0.2982, dF=8)=0.7731). However, the total exploration 
time was reduced in the ketamine treated group (P(t=3.074, 
dF=8)=0.0153, Figure 2C).
In the social affiliation test, rats were allowed to 
choose between contact with an empty containment cup 
and a restrained unfamiliar rat (stranger I) (Figure 2D). 
Analysis of the time spent around each cup revealed 
a significant effect of social affiliation (F(1,16)=12.06, 
P=0.0031). Further analysis by Sidak’s multiple 
comparison showed a significant increase in contact time 
in the compartment holding a conspecific for the control 
group (P =0.0138) but not for ketamine (P=0.1688, 
Figure 2E).
To assess social novelty preference, a second 
unfamiliar rat was placed in the empty cup. Preference 
between the familiar rat (stranger I) and the unknown 
rat (stranger II) was evaluated through the time the 
focal rat spent in contact with each conspecific (Figure 
2F). A two-way ANOVA for “contact time” revealed 
an effect of social novelty (F(1,16)=11.67, P=0.0035). A 
Sidak’s post-hoc test showed increased contact time 
with the novel subject (stranger II) in the control group 
(P=0.0306, Figure 2G), but not in the ketamine group 
(P=0.0976, Figure 2G). 
3.4 Ketamine affected dopaminergic but not glutamatergic 
and GABAergic markers
Prefrontal glutamatergic pyramidal neurons are 
modulated by parvalbumin expressing GABAergic 
interneurons, which were reported to produce reduced 
amounts of GAD67 [34]. We assessed the expression 
levels of several proteins likely to be affected within 
these circuitries (Figure 3A-F). For pyramidal 
glutamatergic neurons we used western blot to analyze 
the levels of VGLUT1 (a glutamate transporter), PSD95 
(a marker of glutamatergic synapses) and NMDAR1 
(a glutamate receptor). No significant differences were 
seen when comparing frontal extracts from ketamine 
exposed with those of control rats (P(U=8)=0.4206, Figure 
3A; P(U=7.5)=0.3413, Figure3B; and P(U=9)=0.5476, Figure 
3C). Parvalbumin and GAD67, markers of GABAergic 
interneurons were also not affected by ketamine (P(t=1.329, 
dF=8)= 0.2204, Figure 3D; and P(t=0.2558, dF=8)=0.8045, Figure 
3E). 
The mRNA levels of the dopamine receptor (DR)1 
and DR2 were not altered by ketamine exposure (P(t=0.5976, 
dF=6)=0.5720, Figure 3H; and P(t=1.248, dF=6)=0.2586, 
Figure 3I). The mRNA expression levels of tyrosine 
hydroxylase (TH), however, were significantly reduced 
in the ketamine treated rats (P(t=3.63, dF=6)=0.0110, Figure 
3J), which may result in decreased dopamine synthesis.
4. Discussion
The present administration schedule aimed at 
further characterizing the persistent effects of a repeated 
administration of ketamine during the adolescent period. 
Our results show that repeated adolescent exposure to 
ketamine lead to a shift towards increased anxiety-like 
states, which was concomitant with impaired social and 
novelty preference. At the molecular level we found 
decreased TH gene expression in the PFC, while the 
frontal levels of parvalbumin, GAD67 and NMDAR, 
hallmarks of frontal GABAergic and glutamatergic 
function, were not significantly affected by ketamine. 
We started our evaluation by conducting an EPM 
test. Our results consistently showed a ketamine-
induced anxiety-like profile. Decreased entries in open 
arms, decreased time in central platform, decreased 
head dipping and augmented environment scanning are 
well-recognized anxiogenic features [35]. Blockade of 
NMDAR through developmental periods was previously 
seen to cause persistent anxiety in the adulthood [36]. 
In contrast, a former study using a similar exposure to 
ketamine found decreased anxiety in the EPM [23]. 
However, in that work the EPM was conducted after a 
locomotion evaluation, which may have affected the EPM 
performance, since previous experience is known to affect 
anxiety-like responses [37]. Of note, agitation, anxiety 
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Figure 2: Ketamine decreased exploration and novelty preference (A) Schematic diagram of sample (acquisition) and 
choice phase conditions in the NOR test. The trial phase was conducted 24h after the sample phase. (B) No significant 
differences were observed for the discrimination index between ketamine exposed and control rats, calculated as the ratio 
TN/(TN+TF)  (TN=time exploring the novel object; TF=time exploring the familiar object). (C) Ketamine decreased total 
exploration time. (D) Schematic diagram for the social affiliation test. The focal rat is free to choose between a social 
target (stranger I, within a wire containment cup) and an object (empty cup). (E) Only the control group displayed the 
expected social preference significantly increasing the time spent in contact with the conspecific. (F) Schematic diagram 
of social novelty preference, a novel rat is added (stranger II) and the focal rat is free to investigate. (G) Control rats spent 
significantly more time in contact with the novel rat. Rats were treated for 7 days with ketamine 30 mg/kg, IP starting on 
PND 35 and tested on PND60, controls received isovolumetric saline. N=5 for both groups.  Results were expressed as 
mean ±SEM. *P<0.05, **P<0.01 compared with the control group (as determined by two-way ANOVA followed by the 
Sidak’s post-hoc test, or two-tailed unpaired t-test for NOR).
and psychosis are predominant features in adolescents 
and young adults using ketamine for recreational 
purposes [38]. In accordance, the participants of a study 
using subanesthetic doses of ketamine in humans (I.V., 
four days) reported self-rated increased anxiety [39], 
which reinforces the relevance of evaluating anxiety in 
translational ketamine models.
Locomotor sensitization due to glutamate antagonists 
is usually only observable soon after ketamine dosing, 
or subsequently to a challenge with another NMDAR 
blocker [12,20,23,40]. Our data are in accordance with 
former studies where no changes in total locomotion 
were observed 24 or 48 h after the last administration of 
ketamine [21,23]. While we did not observe a difference 
in the total distance travelled by both groups, we found 
decreased activity in the central area, which is also 
indicative of increased anxiety and corroborates the EPM 
Journal of Drug and Alcohol Research6
results.
Impairment of working memory has previously 
been reported in NMDAR antagonist models, but the 
extension of the resultant deficits appears to be greatly 
dependent on the nature of the pharmacological approach 
[41,42,43]. The NOR test has consistently been used as a 
first screening for working memory [17] and significant 
deficits were reported for ketamine, MK-801 or PCP 
[43]. Our data showed that chronic exposure to ketamine 
in adolescent rats, under the present administration 
schedule, did not affect the ability to discriminate the 
new object. Nevertheless, the time spent exploring the 
new object was reduced in the ketamine group. Two 
other studies using a similar exposure in adolescent rats 
also reported no effect of chronic ketamine in working 
memory [20,22]. Impaired memory under NMDAR 
antagonists was associated with NMDAR function 
in the prefrontal and hippocampal regions [44,45]. In 
mice exposed to ketamine on PND7, 9 and 11 impaired 
performance in the novel-object recognition and social 
novelty tests was associated to reduced parvalbumin-
expressing cells in the medial PFC [46]. As such, we 
evaluated also the expression levels of several key 
markers for the glutamatergic and GABAergic function 
and found no evidence of glutamatergic hypofunction 
or decreased parvalbumin, which may justify the NOR 
results. Dopamine depletion in the prefrontal cortex 
was also shown to impair retention of familiar objects 
and motivation to explore [47]. Although we did not 
measure the levels of dopamine and its metabolites, we 
found decreased TH mRNA expression levels in the 
PFC of ketamine-exposed rats, which may contribute 
to decreased dopamine synthesis and lead to reduce 
exploration. In response to reduced dopamine, NMDAR 
antagonists were also reported to increase D1R frontal 
availability in chronic users [48]. However, in the 
present study we found no evidence of increased mRNA 
expression for dopamine receptors.
Deficits in social interaction and social recognition 
are associated with impaired social cognition and have 
been widely used to evaluate the action of NMDAR 
antagonists [43]. Our ketamine-exposed rats failed both to 
show significantly decreased contact time with the empty 
enclosure and significantly increased contact time with the 
unfamiliar rat. Reduced contact with a novel conspecific 
may be associated with depressive- and/or anxiety-like 
behaviors, which would be in accordance with our EPM 
results. This is also in accordance with previous studies using 
chronic 25 mg/kg of ketamine in adolescent rats, which 
reported decreased social contact associated to ketamine 
[20]. In adult rats, however, administration of ketamine (30 
mg/kg, 5 consecutive days) did not affect social contact [49], 
which confirms the relevance of independently addressing 
the adolescent period.
Among the wide range of molecular dysfunctions 
reported for NMDAR dysfunction, calcium signalling 
seems to be a unifying element [50]. Post-synaptic 
density scaffolding proteins (mainly PSD-95) have been 
extensively implicated in dynamically modulating calcium 
signalling in synaptic development [50], plasticity [51] 
and stabilization of NMDAR [52]. It was also shown that 
changes in glutamatergic transmission, as those observed 
in in schizophrenia, might be both post-synaptic and pre-
synaptic [53]. A critical component of synaptic plasticity 
in prefrontal presynaptic terminals is VGLUT1 [54]. 
Under the present administration schedule, we found 
no effect of ketamine in the expression levels of PSD-
95 and VGLUT1. Of note, these markers seem to vary 
substantially with the type of protocol used [55], which 
limits their predictive validity. 
5. Conclusion
In summary, we report here that repeated exposure to 
ketamine in adolescent rats lead to increased anxiety as 
demonstrated by the EPM, open field and social contact 
results, but did not impact on working memory or novelty 
preference. In accordance, the present administration 
schedule did not affect glutamatergic e GABAergic 
markers typically associated with frontal dysfunction, 
such as parvalbumin, PSD95 a GAD67 levels. In 
contrast, TH expression was found reduced, which 
may be accompanied by decreased dopamine synthesis 
and therefore involved in the anxiety profile observed. 
Altogether, the present results also indicate that repeated 
adolescent ketamine may be a valuable preclinical model 
for anxiety.
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Figure 3: Ketamine affected dopaminergic but not glutamatergic and GABAergic markers. The protein expression levels 
of the (A) glutamate transporter VGLUT1, (B) post-synaptic density scaffolding protein (PSD95) and (C) the glutamate 
ionotropic receptor NMDAR1 were assessed by Western blot in protein extracts obtained from the prefrontal cortex 
of rats treated with saline solution or with ketamine (30 mg/kg, IP, for 7 days, starting on PND 35 and sacrificed after 
behavioral testing). The levels of (D) Parvalbumin and (E) glutamic acid decarboxylase (GAD67) were also assessed. (F) 
Schematic representation of the glutamatergic/GABAergic interaction at the prefrontal level, showing molecular players 
usually affected in schizophrenic patients. No differences were seen between ketamine and control rats for any of the 
tested markers. Data were normalized to the loading control GAPDH. Results are expressed as mean ± SEM for 5 animals 
per group. (G) Schematic representation of the dopaminergic terminal at the prefrontal levels, showing molecular players 
usually affected in schizophrenic patients. The mRNA expression levels of (H) dopamine D1-like receptors (D1R), (I) 
dopamine D2-like receptors (D2R) and (J) tyrosine-hydroxylase (TH) were assessed in the PFC of rats treated with saline 
solution and with ketamine. No differences were seen between ketamine and control rats for D1R and D2R, while TH was 
significantly reduced in the ketamine-exposed group, which is compatible with a hypodopaminergic frontal state. Results 
were expressed as mean ± SEM, N=4 animals per group. Values displayed were normalized to the control group. * P<0.05 
compared with control group (as determined by two-tailed unpaired t-test).
Journal of Drug and Alcohol Research8
repeated treatment with phencyclidine in mice: implications for 
abnormalities of glutamate release and NMDA-CaMKII signaling. 
Behav Brain Res, 180(2007), 152-160.
[8]  Z. Abdul-Monim, J. C. Neill, and G. P. Reynolds, Sub-chronic 
psychotomimetic phencyclidine induces deficits in reversal learning 
and alterations in parvalbumin-immunoreactive expression in the 
rat. J Psychopharmacol, 21(2007), 198-205.
[9]  Y. K. Choi, S. Snigdha, M. Shahid, J. C. Neill, and F. I. Tarazi, 
Subchronic effects of phencyclidine on dopamine and serotonin 
receptors: implications for schizophrenia. J Mol Neurosci, 
38(2009), 227-235.
[10]  R. J. Beninger, T. W. Baker, M. M. Florczynski, and T. J. 
Banasikowski, Regional differences in the action of antipsychotic 
drugs: implications for cognitive effects in schizophrenic patients. 
Neurotox Res, 18(2010), 229-243.
[11]  G. Keilhoff, A. Becker, G. Grecksch, G. Wolf, and H. G. 
Bernstein, Repeated application of ketamine to rats induces 
changes in the hippocampal expression of parvalbumin, neuronal 
nitric oxide synthase and cFOS similar to those found in human 
schizophrenia. Neuroscience, 126(2004), 591-598.
[12]  A. Becker, B. Peters, H. Schroeder, T. Mann, and G. Huether, 
Ketamine-induced changes in rat behaviour: A possible animal 
model of schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry, 27(2003), 687-700.
[13]  S. Y. Kim, H. Lee, H. J. Kim, E. Bang, and S. H. Lee, In vivo 
and ex vivo evidence for ketamine-induced hyperglutamatergic 
activity in the cerebral cortex of the rat: Potential relevance to 
schizophrenia. NMR Biomed, 24(2011), 1235-1242.
[14]  K. Kittelberger, E. E. Hur, S. Sazegar, V. Keshavan, and B. Kocsis, 
Comparison of the effects of acute and chronic administration of 
ketamine on hippocampal oscillations: relevance for the NMDA 
receptor hypofunction model of schizophrenia. Brain Struct 
Funct, 217(2012), 395-409.
[15]  C. Hjorthoj, N. Albert, and M. Nordentoft, Association of 
Substance Use Disorders with Conversion From Schizotypal 
Disorder to Schizophrenia. JAMA Psychiatry (2018).
[16]  L. Chen, A. Selvendra, A. Stewart, D. Castle, Risk factors in early 
and late onset schizophrenia. Compr Psychiatry, 80(2018), 155-162.
[17]  B. K. Yee and P. Singer, A conceptual and practical guide to the 
behavioural evaluation of animal models of the symptomatology 
and therapy of schizophrenia. Cell Tissue Res, 354(2013), 221-
246.
[18]  C. E. Girardi, N. C. Zanta, and D. Suchecki, Neonatal stress-
induced affective changes in adolescent Wistar rats: early signs of 
schizophrenia-like behavior. Front Behav Neurosci, 8(2014), 319.
[19]  C. J. Alves, A. Magalhaes, P. R. Monteiro, and T. Summavielle, 
Very Long-Term Effects of Chronic Cocaine on Anxiety and 
Stress. In: Preedy VR, editor. The neuroscience of cocaine. 
Academic Press ed. London: Elsevier. pp. (2017) 774.
[20]  C. S. Gama, L. Canever, B. Panizzutti, C. Gubert, and L. Stertz, 
Effects of omega-3 dietary supplement in prevention of positive, 
negative and cognitive symptoms: a study in adolescent rats 
with ketamine-induced model of schizophrenia. Schizophr Res, 
141(2012), 162-167.
[21]  J. Wang, M. Zhou, X. Wang, X. Yang, and M. Wang, Impact of 
ketamine on learning and memory function, neuronal apoptosis 
and its potential association with miR-214 and PTEN in 
adolescent rats. PLoS One, 9(2014), e99855.
[22]  E. Ram, S. Raphaeli, and A. Avital, Prepubertal chronic stress and 
ketamine administration to rats as a neurodevelopmental model 
of schizophrenia symptomatology. Int J Neuropsychopharmacol, 
16(2013), 2307-2314.
[23]  E. M. Parise, L. F. Alcantara, B. L. Warren, K. N. Wright, and 
R. Hadad, Repeated ketamine exposure induces an enduring 
resilient phenotype in adolescent and adult rats. Biol Psychiatry, 
74(2013), 750-759.
[24]  K. J. Schoepfer, C. E. Strong, S. K. Saland, K. N. Wright, and 
M. Kabbaj, Sex- and dose-dependent abuse liability of repeated 
subanesthetic ketamine in rats. Physiol Behav, (2017).
[25]  D. D'Souza and M. Sadananda, Estrous Cycle Phase-Dependent 
Changes in Anxiety- and Depression-Like Profiles in the Late 
Adolescent Wistar-Kyoto Rat. Ann Neurosci, 24(2017), 136-145.
[26]  S. L. Andersen, Trajectories of brain development: point of 
vulnerability or window of opportunity? Neurosci Biobehav Rev, 
27(2003), 3-18.
[27]  A. C. Meirsman, A. Robe, A. de Kerchove d'Exaerde, and B. 
L. Kieffer, GPR88 in A2AR Neurons Enhances Anxiety-Like 
Behaviors. eNeuro 3(2016).
[28]  R. A. Bevins and J. Besheer, Object recognition in rats and 
mice: a one-trial non-matching-to-sample learning task to study 
'recognition memory'. Nat Protoc, 1(2006), 1306-1311.
[29]  A. Ennaceur, S. Michalikova, A. Bradford, and S. Ahmed, 
Detailed analysis of the behavior of Lister and Wistar rats in 
anxiety, object recognition and object location tasks. Behav Brain 
Res, 159(2005), 247-266.
[30]  O. Kaidanovich-Beilin, T. Lipina, I. Vukobradovic, J. Roder, and 
J. R. Woodgett, Assessment of social interaction behaviors. J Vis 
Exp, (2011).
[31]  N. Dawson, B. J. Morris, and J. A. Ratt, Subanaesthetic ketamine 
treatment alters prefrontal cortex connectivity with thalamus and 
ascending subcortical systems. Schizophr Bull, 39(2013), 366-377.
[32]  F. Mueller, F. Musso, M. London, P. de Boer, and N. Zacharias, 
Pharmacological fMRI: Effects of subanesthetic ketamine on 
resting-state functional connectivity in the default mode network, 
salience network, dorsal attention network and executive control 
network. Neuroimage Clin, 19(2018), 745-757.
[33]  F. Faul, E. Erdfelder, A. G. Lang, and A. Buchner, G*Power 
3: a flexible statistical power analysis program for the social, 
behavioral, and biomedical sciences. Behav Res Methods, 
39(2007), 175-191.
[34]  D. A. Lewis, Neuroplasticity of excitatory and inhibitory cortical 
circuits in schizophrenia. Dialogues Clin Neurosci, 11(2009), 
269-280.
[35]  R. J. Rodgers, J. C. Cole, K. Aboualfa, and L. H. Stephenson, 
Ethopharmacological analysis of the effects of putative 
'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol 
Biochem Behav, 52(1995), 805-813.
[36]  K. Wedzony, K. Fijal, M. Mackowiak, A. Chocyk, and W. 
Zajaczkowski, Impact of postnatal blockade of N-methyl-
D-aspartate receptors on rat behavior: a search for a new 
developmental model of schizophrenia. Neuroscience, 153(2008), 
1370-1379.
[37]  S. J. Ballaz, H. Akil, and S. J. Watson, Previous experience affects 
subsequent anxiety-like responses in rats bred for novelty seeking. 
Behav Neurosci, 121(2007), 1113-1118.
[38]  S. S. Kalsi, D. M. Wood, and P. I. Dargan, The epidemiology and 
patterns of acute and chronic toxicity associated with recreational 
ketamine use. Emerg Health Threats J, 4(2011), 7107.
[39]  J. H. Krystal, L. P. Karper, A. Bennett, D. C. D'Souza, and A. 
Abi-Dargham, Interactive effects of subanesthetic ketamine and 
subhypnotic lorazepam in humans. Psychopharmacology (Berl), 
135(1998), 213-229.
[40]  A. Rocha, N. Hart, and K. A. Trujillo, Differences between 
adolescents and adults in the acute effects of PCP and ketamine 
and in sensitization following intermittent administration. 
Pharmacol Biochem Behav, 157(2017), 24-34.
[41]  R. P. Daya, J. K. Bhandari, P. A. Hui, Y. Tian, and T. Farncombe, 
Effects of MK-801 treatment across several pre-clinical analyses 
including a novel assessment of brain metabolic function utilizing 
PET and CT fused imaging in live rats. Neuropharmacology, 
77(2014), 325-333.
Journal of the International Drug Abuse Research Society and the International Narcotics Research Conference 9
[42]  B. Grayson, N. F. Idris, and J. C. Neill, Atypical antipsychotics attenuate 
a sub-chronic PCP-induced cognitive deficit in the novel object 
recognition task in the rat. Behav Brain Res, 184(2007), 31-38.
[43]  J. C. Neill, S. Barnes, S. Cook, B. Grayson, and N. F. Idris, 
Animal models of cognitive dysfunction and negative symptoms of 
schizophrenia: focus on NMDA receptor antagonism. Pharmacol 
Ther, 128(2010), 419-432.
[44]  J. Aura and P. Riekkinen Jr. Blockade of NMDA receptors located 
at the dorsomedial prefrontal cortex impairs spatial working 
memory in rats. Neuroreport, 10(1999), 243-248.
[45]  T. Yoshihara and Y. Ichitani, Hippocampal N-methyl-D-aspartate 
receptor-mediated encoding and retrieval processes in spatial 
working memory: delay-interposed radial maze performance in 
rats. Neuroscience, 129(2004), 1-10.
[46]  V. Jeevakumar, C. Driskill, A. Paine, M. Sobhanian, and H. 
Vakil, Ketamine administration during the second postnatal week 
induces enduring schizophrenia-like behavioral symptoms and 
reduces parvalbumin expression in the medial prefrontal cortex 
of adult mice. Behav Brain Res, 282(2015), 165-175.
[47]  O. Y. Chao, M. E. Pum, and J. P. Huston, The interaction 
between the dopaminergic forebrain projections and the medial 
prefrontal cortex is critical for memory of objects: implications 
for Parkinson's disease. Exp Neurol, 247(2013), 373-382.
[48]  H. Tsukada, S. Nishiyama, D. Fukumoto, K. Sato, and T. 
Kakiuchi, Chronic NMDA antagonism impairs working 
memory, decreases extracellular dopamine, and increases D1 
receptor binding in prefrontal cortex of conscious monkeys. 
Neuropsychopharmacology, 30(2005), 1861-1869.
[49]  A. Becker and G. Grecksch, Ketamine-induced changes in rat 
behaviour: a possible animal model of schizophrenia. Test of 
predictive validity. Prog Neuropsychopharmacol Biol Psychiatry, 
28(2004), 1267-1277.
[50]  M. S. Lidow, Calcium signaling dysfunction in schizophrenia: a 
unifying approach. Brain Res Brain Res Rev, 43(2003), 70-84.
[51]  L. Foa and R. Gasperini, Developmental roles for Homer: more 
than just a pretty scaffold. J Neurochem, 108(2009), 1-10.
[52]  J. F. Sturgill, P. Steiner, B. L. Czervionke, and B. L. Sabatini, 
Distinct domains within PSD-95 mediate synaptic incorporation, 
stabilization, and activity-dependent trafficking. J Neurosci 
29(2009), 12845-12854.
[53]  N. D. Halim, C. S. Weickert, B. W. McClintock, T. M. Hyde, and 
D. R. Weinberger, Presynaptic proteins in the prefrontal cortex 
of patients with schizophrenia and rats with abnormal prefrontal 
development. Mol Psychiatry, 8(2003), 797-810.
[54]  S. Takamori, J. S. Rhee, C. Rosenmund, and R. Jahn, Identification 
of a vesicular glutamate transporter that defines a glutamatergic 
phenotype in neurons. Nature, 407(2000), 189-194.
[55]  V. Micale, J. Kucerova, and A. Sulcova, Leading compounds for 
the validation of animal models of psychopathology. Cell Tissue 
Res, 354(2013), 309-330.
Journal of Drug and Alcohol Research10
